Oramed Pharmaceuticals Inc. (ORMP) 10-Year Financial Performance & Capital Metrics

ORMP • • Industrial / General

HealthcareBiotechnologyMetabolic & Liver DiseasesObesity & Metabolic Disorders

AboutOramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.Show more

Revenue $0 -100.0%
EBITDA -$13M +19.2%
Net Income -$19M -445.8%
EPS (Diluted) -0.47 -435.7%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -12.39% -452.3%
ROIC -6.46% +13.4%
Debt/Equity 0.00 -99.2%
Interest Coverage -14.98 -240.2%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 88 (top 12%)
✓Trading near 52-week high
✓Trading at only 1.0x book value

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Low quality earnings: Net income not backed by cash flow
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-215.82%

EPS CAGR

10Y-

5Y-

3Y-

TTM-222.22%

ROCE

10Y Avg-28.01%

5Y Avg-22.2%

3Y Avg-15.7%

Latest-8.07%

Peer Comparison

Obesity & Metabolic Disorders

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
MNKDMannKind Corporation	1.71B	5.58	57.41	43.5%	9.32%		1.92%
CORTCorcept Therapeutics Incorporated	3.72B	35.39	28.77	39.94%	14.19%	16.65%	5.26%	0.01
GUTSFractyl Health, Inc. Common Stock	302.14M	1.97	-1.22	-22.5%	-40732.33%	-241.68%		2.20
LXRXLexicon Pharmaceuticals, Inc.	465.15M	1.28	-2.03	24.81%	-96.77%	-57.07%		0.74
RZLTRezolute, Inc.	260.56M	2.81	-2.87			-52.45%		0.01
MISTMilestone Pharmaceuticals Inc.	172.89M	2.03	-3.03	-100%		-282.97%		4.17
ALTAltimmune, Inc.	442.41M	4.24	-3.16	-95.31%	-4195.75%	-45.21%		0.01
BIOABioAge Labs, Inc.	771.24M	21.51	-3.24		-12.81%	-27.32%		0.03

Profit & Loss

	Aug 2015	Aug 2016	Aug 2017	Aug 2018	Aug 2019	Aug 2020	Aug 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	641K	2.46M	2.45M	2.7M	2.71M	2.7M	2.7M	1.34M	0
Revenue Growth %	-	-	2.83%	-0%	0.1%	0%	-0%	0%	-0.5%	-1%
Cost of Goods Sold+	0	490K	187K	86K	90K	90K	0	0	0	193K
COGS % of Revenue	-	0.76%	0.08%	0.04%	0.03%	0.03%	-	-	-	-
Gross Profit+	0	151K	2.27M	2.36M	2.61M	2.62M	2.7M	2.7M	1.34M	-193K
Gross Margin %	-	0.24%	0.92%	0.96%	0.97%	0.97%	1%	1%	1%	-
Gross Profit Growth %	-	-	14.03%	0.04%	0.11%	0%	0.03%	0%	-0.5%	-1.14%
Operating Expenses+	7.38M	10.16M	13.04M	16.06M	17.24M	14.47M	26.93M	43.3M	17.11M	12.78M
OpEx % of Revenue	-	15.85%	5.31%	6.56%	6.38%	5.34%	9.96%	16.02%	12.77%	-
Selling, General & Admin	2.6M	2.45M	2.76M	4.08M	3.72M	4.23M	5.94M	15.66M	8.14M	6.46M
SG&A % of Revenue	-	3.83%	1.12%	1.67%	1.38%	1.56%	2.2%	5.79%	6.07%	-
Research & Development	4.78M	7.71M	10.28M	11.98M	13.52M	10.23M	20.99M	27.64M	8.97M	6.32M
R&D % of Revenue	-	12.03%	4.19%	4.89%	5%	3.78%	7.77%	10.23%	6.69%	-
Other Operating Expenses	0	0	0	0	0	0	0	0	0	0
Operating Income+	-7.38M	-10.01M	-10.77M	-13.53M	-14.63M	-11.76M	-24.22M	-40.6M	-15.77M	-12.78M
Operating Margin %	-	-15.62%	-4.39%	-5.52%	-5.41%	-4.34%	-8.96%	-15.02%	-11.77%	-
Operating Income Growth %	-0.25%	-0.36%	-0.08%	-0.26%	-0.08%	0.2%	-1.06%	-0.68%	0.61%	0.19%
EBITDA+	-7.38M	-10.01M	-10.77M	-13.52M	-14.62M	-11.75M	-24.15M	-36.98M	-15.57M	-12.59M
EBITDA Margin %	-	-15.61%	-4.38%	-5.52%	-5.41%	-4.34%	-8.93%	-13.68%	-11.62%	-
EBITDA Growth %	-0.25%	-0.36%	-0.08%	-0.26%	-0.08%	0.2%	-1.05%	-0.53%	0.58%	0.19%
D&A (Non-Cash Add-back)	4K	4K	5K	6K	8K	7K	77K	3.62M	196K	193K
EBIT	-7.38M	-10.01M	-10.77M	-13.53M	0	0	0	-40.6M	7.13M	-15.07M
Net Interest Income+	168K	463K	779K	897K	1.06M	690K	341K	3.57M	4.45M	-853K
Interest Income	168K	474K	785K	903K	1.06M	690K	347K	3.57M	8.03M	0
Interest Expense	0	11K	6K	6K	0	0	6K	0	3.58M	853K
Other Income/Expense	-3K	-17K	-10K	-30K	-450K	-438K	893K	2.93M	20.86M	-3.14M
Pretax Income+	-7.23M	-9.63M	-10.08M	-12.73M	-14.05M	-11.51M	-22.99M	-37.66M	5.09M	-15.92M
Pretax Margin %	-	-15.02%	-4.1%	-5.2%	-5.2%	-4.25%	-8.5%	-13.93%	3.8%	-
Income Tax+	-1K	1.33M	400K	-800K	300K	192K	-2.88M	100K	0	3.18M
Effective Tax Rate %	1%	1.14%	1.04%	1%	1.02%	1%	0.97%	1%	1.09%	1.2%
Net Income+	-7.23M	-10.96M	-10.48M	-12.73M	-14.36M	-11.51M	-22.24M	-37.76M	5.53M	-19.1M
Net Margin %	-	-17.1%	-4.27%	-5.2%	-5.31%	-4.25%	-8.23%	-13.97%	4.12%	-
Net Income Growth %	-0.27%	-0.52%	0.04%	-0.21%	-0.13%	0.2%	-0.93%	-0.7%	1.15%	-4.46%
Net Income (Continuing)	-7.23M	-10.96M	-10.48M	-	-14.36M	-	-	-37.76M	5.09M	-19.1M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	744K	-656K	-928K	-918K
EPS (Diluted)+	-0.67	-0.87	-0.79	-0.86	-0.82	-0.56	-0.78	-0.97	0.14	-0.47
EPS Growth %	-0.08%	-0.3%	0.09%	-0.09%	0.05%	0.32%	-0.39%	-0.24%	1.14%	-4.36%
EPS (Basic)	-0.67	-0.87	-0.79	-0.86	-0.82	-0.56	-0.78	-0.97	0.14	-0.47
Diluted Shares Outstanding	10.82M	12.62M	13.31M	14.88M	17.45M	20.53M	28.47M	39M	40.57M	40.83M
Basic Shares Outstanding	10.82M	12.62M	13.31M	14.88M	17.45M	20.53M	28.47M	39M	40.32M	40.83M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Aug 2015	Aug 2016	Aug 2017	Aug 2018	Aug 2019	Aug 2020	Aug 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	17.37M	31.23M	20.3M	31.04M	33.32M	40.51M	95.34M	157.11M	162.58M	143.22M
Cash & Short-Term Investments	17.23M	31.02M	20.12M	30.46M	32.28M	39.9M	94.14M	155.72M	162.05M	141.93M
Cash Only	3.21M	3.91M	3.97M	5M	3.33M	19.3M	77.25M	40.46M	9.05M	54.42M
Short-Term Investments	14.02M	27.11M	16.15M	25.47M	28.95M	20.6M	16.89M	115.26M	152.99M	87.51M
Accounts Receivable	0	0	0	0	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	127K	198K	159K	574K	1.04M	611K	1.2M	1.39M	537K	1.29M
Total Non-Current Assets+	8.98M	11.6M	18.41M	16.36M	1.34M	4.12M	32.66M	4.53M	57.97M	12.06M
Property, Plant & Equipment	11K	16K	18K	17K	24K	174K	932K	1.81M	1.57M	1.11M
Fixed Asset Turnover	-	40.06x	136.44x	144.06x	112.63x	15.57x	2.90x	1.49x	0.86x	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	8.96M	11.57M	18.38M	16.33M	1.29M	3.93M	6.69M	2.7M	56.37M	10.91M
Other Non-Current Assets	13K	15K	15K	17K	20K	20K	25.04M	24K	34K	34K
Total Assets+	26.35M	42.83M	38.71M	47.4M	34.66M	44.63M	128M	161.64M	220.55M	155.28M
Asset Turnover	-	0.01x	0.06x	0.05x	0.08x	0.06x	0.02x	0.02x	0.01x	-
Asset Growth %	0.21%	0.63%	-0.1%	0.22%	-0.27%	0.29%	1.87%	0.26%	0.36%	-0.3%
Total Current Liabilities+	1.49M	3.62M	5.17M	4.55M	5.31M	4.54M	6.68M	5.75M	53.21M	5.68M
Accounts Payable	953K	1.41M	571K	1.14M	1.34M	594K	2.61M	2.17M	551K	789K
Days Payables Outstanding	-	1.05K	1.11K	4.82K	5.42K	2.41K	-	-	-	1.49K
Short-Term Debt	0	0	0	0	0	44K	130K	247K	51.01M	0
Deferred Revenue (Current)	500K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	0	0
Other Current Liabilities	36K	48K	2.15M	969K	1.27M	601K	-1.37M	-191K	325K	0
Current Ratio	11.67x	8.62x	3.93x	6.82x	6.28x	8.93x	14.27x	27.34x	3.06x	25.19x
Quick Ratio	11.67x	8.62x	3.93x	6.82x	6.28x	8.93x	14.27x	27.34x	3.06x	25.19x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	37K	13.02M	14.31M	11.73M	9.96M	7.22M	4.8M	4.74M	4.44M	4.25M
Long-Term Debt	0	14K	18K	-7.82M	-5.63M	31K	403K	647K	0	0
Capital Lease Obligations	0	0	0	0	0	0	0	0	342K	156K
Deferred Tax Liabilities	26K	11K	11K	11K	11K	11K	11K	11K	0	0
Other Non-Current Liabilities	11K	390K	443K	8.15M	5.92M	229K	145K	82K	102K	90K
Total Liabilities	1.53M	16.64M	19.47M	16.29M	15.27M	11.75M	11.48M	10.49M	57.66M	9.93M
Total Debt+	0	0	0	0	0	75K	533K	894K	51.62M	372K
Net Debt	-3.21M	-3.91M	-3.97M	-5M	-3.33M	-19.22M	-76.71M	-39.57M	42.57M	-54.05M
Debt / Equity	-	-	-	-	-	0.00x	0.00x	0.01x	0.32x	0.00x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-910.00x	-1795.17x	-2254.50x	-	-	-4037.17x	-	-4.40x	-14.98x
Total Equity+	24.83M	26.19M	19.24M	31.11M	19.39M	32.88M	116.52M	151.16M	162.89M	145.35M
Equity Growth %	0.19%	0.05%	-0.27%	0.62%	-0.38%	0.7%	2.54%	0.3%	0.08%	-0.11%
Book Value per Share	2.29	2.07	1.45	2.09	1.11	1.60	4.09	3.88	4.02	3.56
Total Shareholders' Equity	24.83M	26.19M	19.24M	31.11M	19.39M	32.88M	115.77M	151.81M	163.82M	146.26M
Common Stock	138K	157K	163K	207K	208K	284K	424K	476K	485K	480K
Retained Earnings	-35.05M	-46.02M	-56.5M	-69.22M	-81.1M	-92.61M	-114.85M	-163.08M	-157.56M	-176.62M
Treasury Stock	-	-	-	-	-	-	-	-	0	0
Accumulated OCI	558K	106K	401K	702K	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	744K	-656K	-928K	-918K

Cash Flow

	Aug 2015	Aug 2016	Aug 2017	Aug 2018	Aug 2019	Aug 2020	Aug 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-4.95M	4.66M	-5.83M	-14.66M	-12.94M	-12.44M	-21.18M	-27.92M	-10.29M	-8.41M
Operating CF Margin %	-	7.26%	-2.37%	-5.98%	-4.79%	-4.59%	-7.84%	-10.33%	-7.68%	-
Operating CF Growth %	-0.22%	1.94%	-2.25%	-1.51%	0.12%	0.04%	-0.7%	-0.32%	0.63%	0.18%
Net Income	-7.23M	-10.96M	-10.48M	-12.73M	-14.36M	-11.51M	-22.99M	-37.76M	5.09M	-19.1M
Depreciation & Amortization	4K	4K	5K	6K	8K	7K	77K	58K	196K	193K
Stock-Based Compensation	1.35M	634K	1.57M	1.55M	808K	1.17M	2.69M	11.51M	4.21M	4.05M
Deferred Taxes	-20K	-163K	124K	22K	254K	1.01M	-689K	0	0	0
Other Non-Cash Items	93K	101K	72K	99K	55K	38K	1.04M	-778K	-17.09M	3.25M
Working Capital Changes	862K	15.04M	2.87M	-3.6M	290K	-3.16M	-1.31M	-943K	-2.7M	3.2M
Change in Receivables	0	0	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	516K	470K	1.26M	-612K	501K	-816K	2.06M	-376K	-2.23M	3.52M
Cash from Investing+	-3.31M	-16.01M	4.3M	-7M	11.26M	4.63M	-23.76M	30.21M	-73.04M	105.82M
Capital Expenditures	-1K	-9K	-7K	-5K	-15K	-82K	-375K	-496K	-254K	-18K
CapEx % of Revenue	-	0.01%	0%	0%	0.01%	0.03%	0.14%	0.18%	0.19%	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-2K	-2K	-3K	-2K	-3K	-1K	-1K	26K	0	-65K
Cash from Financing+	9.72M	12.04M	1.59M	22.65M	0	23.79M	102.89M	10.78M	51.98M	-52.04M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	8K	1.45M	1.56M	997K	0	13K	22.91M	-721K	0	-2K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-4.95M	4.65M	-5.84M	-14.66M	-12.96M	-12.52M	-21.56M	-28.41M	-10.55M	-8.43M
FCF Margin %	-	7.25%	-2.38%	-5.99%	-4.79%	-4.62%	-7.97%	-10.51%	-7.87%	-
FCF Growth %	-0.21%	1.94%	-2.26%	-1.51%	0.12%	0.03%	-0.72%	-0.32%	0.63%	0.2%
FCF per Share	-0.46	0.37	-0.44	-0.99	-0.74	-0.61	-0.76	-0.73	-0.26	-0.21
FCF Conversion (FCF/Net Income)	0.68x	-0.42x	0.56x	1.15x	0.90x	1.08x	0.95x	0.74x	-1.86x	0.44x
Interest Paid	-	-	-	-	-	-	-	-	574K	2.32M
Taxes Paid	-	-	-	-	-	-	-	-	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-31.7%	-42.98%	-46.14%	-50.55%	-56.85%	-44.04%	-29.77%	-28.22%	3.52%	-12.39%
Return on Invested Capital (ROIC)	-27.25%	-34.2%	-43.02%	-49.03%	-52.03%	-59.33%	-67.96%	-40.23%	-7.46%	-6.46%
Gross Margin	-	23.56%	92.39%	96.49%	96.67%	96.68%	100%	100%	100%	-
Net Margin	-	-1710.45%	-426.71%	-519.68%	-531.08%	-424.76%	-822.72%	-1397.11%	412.31%	-
Debt / Equity	-	-	-	-	-	0.00x	0.00x	0.01x	0.32x	0.00x
Interest Coverage	-	-910.00x	-1795.17x	-2254.50x	-	-	-4037.17x	-	-4.40x	-14.98x
FCF Conversion	0.68x	-0.42x	0.56x	1.15x	0.90x	1.08x	0.95x	0.74x	-1.86x	0.44x
Revenue Growth	-	-	283.15%	-0.29%	10.37%	0.26%	-0.26%	0%	-50.43%	-100%

Frequently Asked Questions

Growth & Financials

Oramed Pharmaceuticals Inc. (ORMP) reported $2.0M in revenue for fiscal year 2024. This represents a 913% increase from $0.2M in 2011.

Oramed Pharmaceuticals Inc. (ORMP) saw revenue decline by 100.0% over the past year.

Oramed Pharmaceuticals Inc. (ORMP) reported a net loss of $24.2M for fiscal year 2024.

Dividend & Returns

Oramed Pharmaceuticals Inc. (ORMP) has a return on equity (ROE) of -12.4%. Negative ROE indicates the company is unprofitable.

Oramed Pharmaceuticals Inc. (ORMP) had negative free cash flow of $16.1M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Oramed Pharmaceuticals Inc. (ORMP) 10-Year Financial Performance & Capital Metrics

ORMP • • Industrial / General

HealthcareBiotechnologyMetabolic & Liver DiseasesObesity & Metabolic Disorders

Revenue $0 -100.0%
EBITDA -$13M +19.2%
Net Income -$19M -445.8%
EPS (Diluted) -0.47 -435.7%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -12.39% -452.3%
ROIC -6.46% +13.4%
Debt/Equity 0.00 -99.2%
Interest Coverage -14.98 -240.2%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 88 (top 12%)
✓Trading near 52-week high
✓Trading at only 1.0x book value

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Low quality earnings: Net income not backed by cash flow
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-215.82%

EPS CAGR

10Y-

5Y-

3Y-

TTM-222.22%

ROCE

10Y Avg-28.01%

5Y Avg-22.2%

3Y Avg-15.7%

Latest-8.07%

Peer Comparison

Obesity & Metabolic Disorders

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
MNKDMannKind Corporation	1.71B	5.58	57.41	43.5%	9.32%		1.92%
CORTCorcept Therapeutics Incorporated	3.72B	35.39	28.77	39.94%	14.19%	16.65%	5.26%	0.01
GUTSFractyl Health, Inc. Common Stock	302.14M	1.97	-1.22	-22.5%	-40732.33%	-241.68%		2.20
LXRXLexicon Pharmaceuticals, Inc.	465.15M	1.28	-2.03	24.81%	-96.77%	-57.07%		0.74
RZLTRezolute, Inc.	260.56M	2.81	-2.87			-52.45%		0.01
MISTMilestone Pharmaceuticals Inc.	172.89M	2.03	-3.03	-100%		-282.97%		4.17
ALTAltimmune, Inc.	442.41M	4.24	-3.16	-95.31%	-4195.75%	-45.21%		0.01
BIOABioAge Labs, Inc.	771.24M	21.51	-3.24		-12.81%	-27.32%		0.03

Profit & Loss

	Aug 2015	Aug 2016	Aug 2017	Aug 2018	Aug 2019	Aug 2020	Aug 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	641K	2.46M	2.45M	2.7M	2.71M	2.7M	2.7M	1.34M	0
Revenue Growth %	-	-	2.83%	-0%	0.1%	0%	-0%	0%	-0.5%	-1%
Cost of Goods Sold+	0	490K	187K	86K	90K	90K	0	0	0	193K
COGS % of Revenue	-	0.76%	0.08%	0.04%	0.03%	0.03%	-	-	-	-
Gross Profit+	0	151K	2.27M	2.36M	2.61M	2.62M	2.7M	2.7M	1.34M	-193K
Gross Margin %	-	0.24%	0.92%	0.96%	0.97%	0.97%	1%	1%	1%	-
Gross Profit Growth %	-	-	14.03%	0.04%	0.11%	0%	0.03%	0%	-0.5%	-1.14%
Operating Expenses+	7.38M	10.16M	13.04M	16.06M	17.24M	14.47M	26.93M	43.3M	17.11M	12.78M
OpEx % of Revenue	-	15.85%	5.31%	6.56%	6.38%	5.34%	9.96%	16.02%	12.77%	-
Selling, General & Admin	2.6M	2.45M	2.76M	4.08M	3.72M	4.23M	5.94M	15.66M	8.14M	6.46M
SG&A % of Revenue	-	3.83%	1.12%	1.67%	1.38%	1.56%	2.2%	5.79%	6.07%	-
Research & Development	4.78M	7.71M	10.28M	11.98M	13.52M	10.23M	20.99M	27.64M	8.97M	6.32M
R&D % of Revenue	-	12.03%	4.19%	4.89%	5%	3.78%	7.77%	10.23%	6.69%	-
Other Operating Expenses	0	0	0	0	0	0	0	0	0	0
Operating Income+	-7.38M	-10.01M	-10.77M	-13.53M	-14.63M	-11.76M	-24.22M	-40.6M	-15.77M	-12.78M
Operating Margin %	-	-15.62%	-4.39%	-5.52%	-5.41%	-4.34%	-8.96%	-15.02%	-11.77%	-
Operating Income Growth %	-0.25%	-0.36%	-0.08%	-0.26%	-0.08%	0.2%	-1.06%	-0.68%	0.61%	0.19%
EBITDA+	-7.38M	-10.01M	-10.77M	-13.52M	-14.62M	-11.75M	-24.15M	-36.98M	-15.57M	-12.59M
EBITDA Margin %	-	-15.61%	-4.38%	-5.52%	-5.41%	-4.34%	-8.93%	-13.68%	-11.62%	-
EBITDA Growth %	-0.25%	-0.36%	-0.08%	-0.26%	-0.08%	0.2%	-1.05%	-0.53%	0.58%	0.19%
D&A (Non-Cash Add-back)	4K	4K	5K	6K	8K	7K	77K	3.62M	196K	193K
EBIT	-7.38M	-10.01M	-10.77M	-13.53M	0	0	0	-40.6M	7.13M	-15.07M
Net Interest Income+	168K	463K	779K	897K	1.06M	690K	341K	3.57M	4.45M	-853K
Interest Income	168K	474K	785K	903K	1.06M	690K	347K	3.57M	8.03M	0
Interest Expense	0	11K	6K	6K	0	0	6K	0	3.58M	853K
Other Income/Expense	-3K	-17K	-10K	-30K	-450K	-438K	893K	2.93M	20.86M	-3.14M
Pretax Income+	-7.23M	-9.63M	-10.08M	-12.73M	-14.05M	-11.51M	-22.99M	-37.66M	5.09M	-15.92M
Pretax Margin %	-	-15.02%	-4.1%	-5.2%	-5.2%	-4.25%	-8.5%	-13.93%	3.8%	-
Income Tax+	-1K	1.33M	400K	-800K	300K	192K	-2.88M	100K	0	3.18M
Effective Tax Rate %	1%	1.14%	1.04%	1%	1.02%	1%	0.97%	1%	1.09%	1.2%
Net Income+	-7.23M	-10.96M	-10.48M	-12.73M	-14.36M	-11.51M	-22.24M	-37.76M	5.53M	-19.1M
Net Margin %	-	-17.1%	-4.27%	-5.2%	-5.31%	-4.25%	-8.23%	-13.97%	4.12%	-
Net Income Growth %	-0.27%	-0.52%	0.04%	-0.21%	-0.13%	0.2%	-0.93%	-0.7%	1.15%	-4.46%
Net Income (Continuing)	-7.23M	-10.96M	-10.48M	-	-14.36M	-	-	-37.76M	5.09M	-19.1M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	744K	-656K	-928K	-918K
EPS (Diluted)+	-0.67	-0.87	-0.79	-0.86	-0.82	-0.56	-0.78	-0.97	0.14	-0.47
EPS Growth %	-0.08%	-0.3%	0.09%	-0.09%	0.05%	0.32%	-0.39%	-0.24%	1.14%	-4.36%
EPS (Basic)	-0.67	-0.87	-0.79	-0.86	-0.82	-0.56	-0.78	-0.97	0.14	-0.47
Diluted Shares Outstanding	10.82M	12.62M	13.31M	14.88M	17.45M	20.53M	28.47M	39M	40.57M	40.83M
Basic Shares Outstanding	10.82M	12.62M	13.31M	14.88M	17.45M	20.53M	28.47M	39M	40.32M	40.83M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Aug 2015	Aug 2016	Aug 2017	Aug 2018	Aug 2019	Aug 2020	Aug 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	17.37M	31.23M	20.3M	31.04M	33.32M	40.51M	95.34M	157.11M	162.58M	143.22M
Cash & Short-Term Investments	17.23M	31.02M	20.12M	30.46M	32.28M	39.9M	94.14M	155.72M	162.05M	141.93M
Cash Only	3.21M	3.91M	3.97M	5M	3.33M	19.3M	77.25M	40.46M	9.05M	54.42M
Short-Term Investments	14.02M	27.11M	16.15M	25.47M	28.95M	20.6M	16.89M	115.26M	152.99M	87.51M
Accounts Receivable	0	0	0	0	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	127K	198K	159K	574K	1.04M	611K	1.2M	1.39M	537K	1.29M
Total Non-Current Assets+	8.98M	11.6M	18.41M	16.36M	1.34M	4.12M	32.66M	4.53M	57.97M	12.06M
Property, Plant & Equipment	11K	16K	18K	17K	24K	174K	932K	1.81M	1.57M	1.11M
Fixed Asset Turnover	-	40.06x	136.44x	144.06x	112.63x	15.57x	2.90x	1.49x	0.86x	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	8.96M	11.57M	18.38M	16.33M	1.29M	3.93M	6.69M	2.7M	56.37M	10.91M
Other Non-Current Assets	13K	15K	15K	17K	20K	20K	25.04M	24K	34K	34K
Total Assets+	26.35M	42.83M	38.71M	47.4M	34.66M	44.63M	128M	161.64M	220.55M	155.28M
Asset Turnover	-	0.01x	0.06x	0.05x	0.08x	0.06x	0.02x	0.02x	0.01x	-
Asset Growth %	0.21%	0.63%	-0.1%	0.22%	-0.27%	0.29%	1.87%	0.26%	0.36%	-0.3%
Total Current Liabilities+	1.49M	3.62M	5.17M	4.55M	5.31M	4.54M	6.68M	5.75M	53.21M	5.68M
Accounts Payable	953K	1.41M	571K	1.14M	1.34M	594K	2.61M	2.17M	551K	789K
Days Payables Outstanding	-	1.05K	1.11K	4.82K	5.42K	2.41K	-	-	-	1.49K
Short-Term Debt	0	0	0	0	0	44K	130K	247K	51.01M	0
Deferred Revenue (Current)	500K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	0	0
Other Current Liabilities	36K	48K	2.15M	969K	1.27M	601K	-1.37M	-191K	325K	0
Current Ratio	11.67x	8.62x	3.93x	6.82x	6.28x	8.93x	14.27x	27.34x	3.06x	25.19x
Quick Ratio	11.67x	8.62x	3.93x	6.82x	6.28x	8.93x	14.27x	27.34x	3.06x	25.19x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	37K	13.02M	14.31M	11.73M	9.96M	7.22M	4.8M	4.74M	4.44M	4.25M
Long-Term Debt	0	14K	18K	-7.82M	-5.63M	31K	403K	647K	0	0
Capital Lease Obligations	0	0	0	0	0	0	0	0	342K	156K
Deferred Tax Liabilities	26K	11K	11K	11K	11K	11K	11K	11K	0	0
Other Non-Current Liabilities	11K	390K	443K	8.15M	5.92M	229K	145K	82K	102K	90K
Total Liabilities	1.53M	16.64M	19.47M	16.29M	15.27M	11.75M	11.48M	10.49M	57.66M	9.93M
Total Debt+	0	0	0	0	0	75K	533K	894K	51.62M	372K
Net Debt	-3.21M	-3.91M	-3.97M	-5M	-3.33M	-19.22M	-76.71M	-39.57M	42.57M	-54.05M
Debt / Equity	-	-	-	-	-	0.00x	0.00x	0.01x	0.32x	0.00x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-910.00x	-1795.17x	-2254.50x	-	-	-4037.17x	-	-4.40x	-14.98x
Total Equity+	24.83M	26.19M	19.24M	31.11M	19.39M	32.88M	116.52M	151.16M	162.89M	145.35M
Equity Growth %	0.19%	0.05%	-0.27%	0.62%	-0.38%	0.7%	2.54%	0.3%	0.08%	-0.11%
Book Value per Share	2.29	2.07	1.45	2.09	1.11	1.60	4.09	3.88	4.02	3.56
Total Shareholders' Equity	24.83M	26.19M	19.24M	31.11M	19.39M	32.88M	115.77M	151.81M	163.82M	146.26M
Common Stock	138K	157K	163K	207K	208K	284K	424K	476K	485K	480K
Retained Earnings	-35.05M	-46.02M	-56.5M	-69.22M	-81.1M	-92.61M	-114.85M	-163.08M	-157.56M	-176.62M
Treasury Stock	-	-	-	-	-	-	-	-	0	0
Accumulated OCI	558K	106K	401K	702K	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	744K	-656K	-928K	-918K

Cash Flow

	Aug 2015	Aug 2016	Aug 2017	Aug 2018	Aug 2019	Aug 2020	Aug 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-4.95M	4.66M	-5.83M	-14.66M	-12.94M	-12.44M	-21.18M	-27.92M	-10.29M	-8.41M
Operating CF Margin %	-	7.26%	-2.37%	-5.98%	-4.79%	-4.59%	-7.84%	-10.33%	-7.68%	-
Operating CF Growth %	-0.22%	1.94%	-2.25%	-1.51%	0.12%	0.04%	-0.7%	-0.32%	0.63%	0.18%
Net Income	-7.23M	-10.96M	-10.48M	-12.73M	-14.36M	-11.51M	-22.99M	-37.76M	5.09M	-19.1M
Depreciation & Amortization	4K	4K	5K	6K	8K	7K	77K	58K	196K	193K
Stock-Based Compensation	1.35M	634K	1.57M	1.55M	808K	1.17M	2.69M	11.51M	4.21M	4.05M
Deferred Taxes	-20K	-163K	124K	22K	254K	1.01M	-689K	0	0	0
Other Non-Cash Items	93K	101K	72K	99K	55K	38K	1.04M	-778K	-17.09M	3.25M
Working Capital Changes	862K	15.04M	2.87M	-3.6M	290K	-3.16M	-1.31M	-943K	-2.7M	3.2M
Change in Receivables	0	0	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	516K	470K	1.26M	-612K	501K	-816K	2.06M	-376K	-2.23M	3.52M
Cash from Investing+	-3.31M	-16.01M	4.3M	-7M	11.26M	4.63M	-23.76M	30.21M	-73.04M	105.82M
Capital Expenditures	-1K	-9K	-7K	-5K	-15K	-82K	-375K	-496K	-254K	-18K
CapEx % of Revenue	-	0.01%	0%	0%	0.01%	0.03%	0.14%	0.18%	0.19%	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-2K	-2K	-3K	-2K	-3K	-1K	-1K	26K	0	-65K
Cash from Financing+	9.72M	12.04M	1.59M	22.65M	0	23.79M	102.89M	10.78M	51.98M	-52.04M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	8K	1.45M	1.56M	997K	0	13K	22.91M	-721K	0	-2K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-4.95M	4.65M	-5.84M	-14.66M	-12.96M	-12.52M	-21.56M	-28.41M	-10.55M	-8.43M
FCF Margin %	-	7.25%	-2.38%	-5.99%	-4.79%	-4.62%	-7.97%	-10.51%	-7.87%	-
FCF Growth %	-0.21%	1.94%	-2.26%	-1.51%	0.12%	0.03%	-0.72%	-0.32%	0.63%	0.2%
FCF per Share	-0.46	0.37	-0.44	-0.99	-0.74	-0.61	-0.76	-0.73	-0.26	-0.21
FCF Conversion (FCF/Net Income)	0.68x	-0.42x	0.56x	1.15x	0.90x	1.08x	0.95x	0.74x	-1.86x	0.44x
Interest Paid	-	-	-	-	-	-	-	-	574K	2.32M
Taxes Paid	-	-	-	-	-	-	-	-	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-31.7%	-42.98%	-46.14%	-50.55%	-56.85%	-44.04%	-29.77%	-28.22%	3.52%	-12.39%
Return on Invested Capital (ROIC)	-27.25%	-34.2%	-43.02%	-49.03%	-52.03%	-59.33%	-67.96%	-40.23%	-7.46%	-6.46%
Gross Margin	-	23.56%	92.39%	96.49%	96.67%	96.68%	100%	100%	100%	-
Net Margin	-	-1710.45%	-426.71%	-519.68%	-531.08%	-424.76%	-822.72%	-1397.11%	412.31%	-
Debt / Equity	-	-	-	-	-	0.00x	0.00x	0.01x	0.32x	0.00x
Interest Coverage	-	-910.00x	-1795.17x	-2254.50x	-	-	-4037.17x	-	-4.40x	-14.98x
FCF Conversion	0.68x	-0.42x	0.56x	1.15x	0.90x	1.08x	0.95x	0.74x	-1.86x	0.44x
Revenue Growth	-	-	283.15%	-0.29%	10.37%	0.26%	-0.26%	0%	-50.43%	-100%

Frequently Asked Questions

Growth & Financials

Oramed Pharmaceuticals Inc. (ORMP) reported $2.0M in revenue for fiscal year 2024. This represents a 913% increase from $0.2M in 2011.

Oramed Pharmaceuticals Inc. (ORMP) saw revenue decline by 100.0% over the past year.

Oramed Pharmaceuticals Inc. (ORMP) reported a net loss of $24.2M for fiscal year 2024.

Dividend & Returns

Oramed Pharmaceuticals Inc. (ORMP) has a return on equity (ROE) of -12.4%. Negative ROE indicates the company is unprofitable.

Oramed Pharmaceuticals Inc. (ORMP) had negative free cash flow of $16.1M in fiscal year 2024, likely due to heavy capital investments.